Overview
- This volume will bring together a review of research being carried out by international experts in this field, detailing treatment and research approaches in several forms of malignant brain tumours
- This volume will prove as a highly relevant, detailed and up-to-date account of the research and findings in the field of brain cancer research and resistance to currently developed targeted therapies
- This volume will also contain information on the repurposing of drugs in an attempt to circumvent drug resistance, use of small molecule inhibitors in GBM treatment, mechanisms of secondary brain metastasis, drug resistance and state-of-the-art imaging of targeted therapies
- Includes supplementary material: sn.pub/extras
Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics (RTACT)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (11 chapters)
-
Front Matter
-
Back Matter
Keywords
About this book
This volume will bring together a review of research being carried out by international experts in this field, detailing treatment and research approaches in several forms of malignant brain tumors. These include glioblastoma (GBM), a highly aggressive and fatal form of astrocytoma which accounts for 80% of newly diagnosed brain tumor patients per year, and meningioma, of which 10% are malignant and extremely resistant to targeted therapies. The volume will also include a discussion of methods to overcome blood-brain barrier exclusion for more efficient targeted drug delivery in all forms of brain cancer treatment. The volume will include information on the repurposing of drugs in an attempt to circumvent drug resistance, use of small molecule inhibitors in GBM treatment, mechanisms of secondary brain metastasis, drug resistance, and state-of-the-art imaging of targeted therapies.
Reviews
Editors and Affiliations
About the editor
Bibliographic Information
Book Title: Resistance to Targeted Therapies Against Adult Brain Cancers
Editors: Amanda Tivnan
Series Title: Resistance to Targeted Anti-Cancer Therapeutics
DOI: https://doi.org/10.1007/978-3-319-46505-0
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer International Publishing AG 2016
Hardcover ISBN: 978-3-319-46504-3Published: 16 December 2016
Softcover ISBN: 978-3-319-83531-0Published: 04 July 2018
eBook ISBN: 978-3-319-46505-0Published: 26 November 2016
Series ISSN: 2196-5501
Series E-ISSN: 2196-551X
Edition Number: 1
Number of Pages: XVI, 260
Number of Illustrations: 3 b/w illustrations, 16 illustrations in colour
Topics: Cancer Research